Autolus Therapeutics vs ARS Pharmaceuticals
Autolus Therapeutics and ARS Pharmaceuticals are similar in size: $75.4m and $84.3m of revenue in their latest fiscal years. Autolus Therapeutics grew faster (644.9% against -5.5%). ARS Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -203.3% against -381.4%.
| Latest fiscal year | Autolus TherapeuticsAUTL, 2025 | ARS PharmaceuticalsSPRY, 2025 |
|---|---|---|
| Revenue | $75.4m | $84.3m |
| Revenue growth | 644.9% | -5.5% |
| Net income | −$288m | −$171m |
| Operating margin | -358.9% | — |
| Net margin | -381.4% | -203.3% |
| Return on equity | -95.0% | -92.3% |
| Free cash flow | −$303m | −$171m |
| Cash | $104m | $41.3m |
| Total debt | $0 | $96.4m |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 754 | 158 |
| Market value | $371m | $298m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 1 sales | 0 buys, 5 sales |